Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
Date:4/5/2011

SAN FRANCISCO, April 5, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) ("the Company") and raised its twelve month target price to $3.22. Ross Silver, Principal Analyst at Vista Partners stated, "The Company stated that it has reached an agreement with the FDA on the design of a pivotal, randomized, controlled, and blinded Phase III clinical trial of DAVANAT®. We believe this to be a significant milestone in the Company's history and could open the door for a potential partnership." Mr. Silver continued, "The Company has stated that it plans to initiate a Phase I/ll clinical trial of DAVANAT® in combination with a melanoma vaccine in collaboration with the Ludwig Institute in Brussels, Belgium in the third quarter.  This collaboration to date has shown that DAVANAT® activates tumor-specific cytotoxic T-cells allowing them to kill tumor cells. In addition, the Company plans to obtain an IND for treatment of liver fibrosis in the fourth quarter and plans to initiate clinical trials in early 2012."  Mr. Silver concludes, "We believe Pro-Pharmaceuticals to be one of the most attractive small cap biotechnology companies we have come across as a result of its robust clinical pipeline, which includes two candidates entering the clinic later this year and a late stage clinical candidate for metastatic colorectal cancer, all of which would compete in multi-billion dollar markets if approved. In addition, the Company has a strong management team, which is led by CEO Dr. Peter Traber, the former Chief Medical Officer of GlaxoSmithKline plc."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain
'/>"/>

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harris Corporation Awarded Contract to Provide Engineering and Enterprise Support to Veteran Affairss VistA Imaging System
2. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
3. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
4. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
5. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
6. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
7. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
8. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
9. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
10. Watson Confirms EVISTA(R) Patent Challenge
11. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) today announced ... Officer and Executive Vice President. Mr. Singh died suddenly and ... "Sorrento is deeply saddened and shocked by the loss of ... Amar,s family and friends," said Henry Ji , Ph.D., ... Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where ...
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... AT&T * today announced that the Arkansas Department ... mobile flu clinic solution to help the agency more efficiently ... to extend the use of the application to other year-round ... As an important part of its mission to ...
... 2011 Inhibitex, Inc. (Nasdaq: INHX ) today ... shares of its common stock, at a purchase price of ... The net proceeds to Inhibitex from the sale of the ... are expected to be approximately $44 million.  Inhibitex has granted ...
Cached Medicine Technology:Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 2Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 3Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 4Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:8/2/2014)... (PRWEB) August 02, 2014 Apervi, ... orchestration platform simplifying data engineering for big data, ... is one of the first Enterprise data engineering ... Spark. Databricks, the company founded by the creators ... as a means to encourage new development on ...
(Date:8/2/2014)... (PRWEB) August 02, 2014 CEDR ... nation's number one provider of customized medical and dental ... major dental-industry conferences this fall. CEDR’s CEO will be ... September and early December. , From September 4-6, CEDR ... Office Managers (AADOM) Dental Managers Conference in San Diego, ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
Breaking Medicine News(10 mins):Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 2Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 3Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... inflammation and loss of cartilage in joints, is likely ... // ,Researchers led by David Felson, a professor ... with symptomatic osteoarthritis of the knee for 30 months. ... the online edition of BBC News. ,The ...
... for capacity Building', Ministry of Health and Family ... Rs. 1.50 crores or actual, whichever is less, ... State Hospitals of towns/cities located on National Highways. ... Road Transport and Highways and Ministry of Health ...
... an amazing figure at the cost of their own health. ... large population is opting for laxative abuse. ,Assumptions about ... which proved that 20% of women who wanted to lose ... students. ,Though these women start with few pills a ...
... 9th of November, urging parents to prevent use of fluoridated ... dentists are concerned about the exposure to fluoride at such ... teeth it might permanently damage them, apart from which it ... cancer boys. ,This advice is not noticed by many ...
... of food poison. Then, fame came as a temporary ... 'miracle poison' and used for an increasing number of ... Mayo Clinic Health Letter covers how this drug works ... ,Botulinum toxin blocks communication between nerves and muscles. Food ...
... the increasing number of children pronounced as juvenile diabetics, it ... such diseases //on their little ones. What used to ... silently attacking children, and it is imperative that parents and ... hand. ,New data from the International Diabetes ...
Cached Medicine News:Health News:Laxatives are Not the Right Option for Losing Weight 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: